GENIE 17.0-Public Release

<

>

Featured Cancer

March is Colorectal awareness month. As highlighted in a recent blog post, new advances are being made in the use of vaccines for treatment of this disease.​
​
The #AACRGENIE 17.0 public release provides a detailed look at the genomic landscape of colorectal cancer, offering valuable insights. The registry includes 19,544 patients and 20,599 samples, helping to deepen our understanding of this cancer. TP53, APC, KRAS and PIK3CA are the most frequently mutated genes among other key mutations. ​
​
These data highlight several clinically actionable alterations, including BRAF V600E and KRAS G12C mutations, ERBB2 amplification, as well as NTRK1, NTRK2, NTRK3, and RET fusions.

In addition, the #AACRGENIE BioPharma Collaborative (BPC) Colorectal 2.0-public cohort contains deep clinical annotation on 1,485 patients and 1,551 samples from the main GENIE registry.​

The LATEST

• GENIE data was presented in a poster session at ASCO #GU25.
  Abstract Title: DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.
• The latest GENIE publication: Collaborating across sectors in service of open science, precision oncology, and patients: an overview of the AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC) – ScienceDirect, Elsevier, Volume 7, March 2025.
• A snapshot of a year of progress: 2024_Year_in_Review.
• Watch the latest Believe in Progress episode: AACR Project GENIE: A Conversation with Shawn M. Sweeney, PhD, and Philippe L. Bedard, MD.
• New public data portal available from Sage Bionetworks.
• The BioPharma Collaborative’s CRC v2.0-Public and NSCLC 2.0-Public datasets are now available.
• Learn more about AACR Project GENIE data included as part of sotorasib regulatory approval.

Visit AACR PROJECT GENIE® BLOG for further information.